More studies needed after cabazitaxel shows promise in dedifferentiated liposarcoma

In a nonrandomized phase 2 clinical trial, patients with advanced dedifferentiated liposarcoma (DDLPS) treated with cabazitaxel had a median progression-free survival of 6.5 months, exceeding expectations and warranting investigation in phase 3 trials. A total of 38 patients with advanced histologically proven DDLPS with evidence of disease progression within the...